| PMID : |
 |
 (22566860) |
|
| titre : |
|
Immunization route dictates cross-priming efficiency and impacts the optimal timing of adjuvant delivery. |
|
| auteur(s) : |
|
Isabelle Bouvier1, Hélène Jusforgues-Saklani1, Annick Lim2, Fabrice Lemaître3, Brigitte Lemercier2, Charlotte Auriau1, Marie-Anne Nicola4, Sandrine Leroy5, Helen K Law6, Antonio Bandeira7, James J Moon8, Philippe Bousso3, Matthew L Albert ( ) 1 |
|
| laboratoire : |
|
|
|
| résumé : |
|
Delivery of cell-associated antigen represents an important strategy for vaccination. While many experimental models have been developed in order to define the critical parameters for efficient cross-priming, few have utilized quantitative methods that permit the study of the endogenous repertoire. Comparing different strategies of immunization, we report that local delivery of cell-associated antigen results in delayed T cell cross-priming due to the increased time required for antigen capture and presentation. In comparison, delivery of disseminated antigen resulted in rapid T cell priming. Surprisingly, local injection of cell-associated antigen, while slower, resulted in the differentiation of a more robust, polyfunctional, effector response. We also evaluated the combination of cell-associated antigen with poly I:C delivery and observed an immunization route-specific effect regarding the optimal timing of innate immune stimulation. These studies highlight the importance of considering the timing and persistence of antigen presentation, and suggest that intradermal injection with delayed adjuvant delivery is the optimal strategy for achieving CD8⁺ T cell cross-priming. |
|
| domaine : |
|
Sciences du Vivant/Immunologie
|
|
langue du texte
intégral : |
|
Anglais |
|
| ISSN : |
|
1664-3224 |
|
|
| type de publication : |
|
Articles dans des revues avec comité de lecture |
|
| DOI : |
|
10.3389/fimmu.2011.00071 |
|
| journal : |
|
Front Immunol |
|
| Audience : |
|
internationale |
|
| date de publication : |
|
2011 |
|
date de publication
électronique : |
|
08/12/2011 |
|
| volume : |
|
2 |
|
| page, identifiant, ... : |
|
71 |
|
|
| contrat, financement : |
|
This work was supported by La Ligue contre le cancer and the EURYIscheme and by the Association pour la Recherche sur le Cancer (projectDOC20110603227). |
|
